The resistome is the totality of the ancient genetic base of antibiotic-resistant genes among bacterial species. In the past, the resistome was wholly the subject of the natural world and the antibiotics that developed within it. However, ever since the use and misuse of antibiotics by humans began, the balance between the resistome and antibiotics has turned into a race between the emergence of highly antibiotic-resistant “superbugs” and the development of novel antibiotic compounds and antibiotic techniques. Among those superbugs that have become of human concern in recent years, Methicillin-resistant S. aureus (MRSA) is one of the most important. This paper aims to outline a possible novel vesicle vaccine that is effective against MRSA, and additionally, the process by which the vaccine might be experimentally created.
SV2A is a synaptic vesicle protein, which participates in the regulation of neurotransmitter release in humans. SV2A is expressed in neurons and endocrine cells. The exact function of SV2A is still unknown, but it has been identified that SV2A is the binding site for the antiepileptic drug, levetiracetam. Levetiracetam reduces presynaptic glutamate release, especially in neurons with high frequency firing.
